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Children’s Hospital, AO Spedali Civili Brescia, Brescia, ItalyAbstractIn the last few years, many reports have conﬁrmed the presence of WU, KI and Merkel cell (MC) polyomaviruses (PyV) in respiratory samples
wordwide, but their pathogenic role in patients with underlying conditions such as cystic ﬁbrosis is still debated. To determine the prevalence
of MCPyV, WUPyV and KIPyV, we conducted a 1-year-long microbiological testing of respiratory specimens from 93 patients with cystic
ﬁbrosis in Brescia, Italy. We detected PyV DNA in 94 out of 337 analysed specimens. KIPyV was the most common virus detected
(12.1%), followed by WUPyV (8.9%) and MCPyV (6.8%). We found an intriguing association between the presence of MCPyV and the
concurrent isolation of Pseudomonas aeruginosa, as well as with the patient status, classiﬁed as chronically colonized with P. aeruginosa.
Our study adds perspective on the prevalence and the potential pathogenic role of PyV infections.
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E-mail: simona.ﬁorentini@unibs.itIntroductionCystic ﬁbrosis (CF) is a multiorgan genetic disorder charac-
terized by recurrent pulmonary exacerbation. Chronic bacte-
rial infections are the main cause of lung damage with less
known about the role of viral infections [1–3].
Polyomaviruses (PyVs) are small, non-enveloped dsDNA
viruses extensively studied over decades. In 2007, two new
human PyVs, KI (KIPyV) and WU (WUPyV), were identiﬁed in
specimens from patients with respiratory illness [4,5]. and many
reports have then conﬁrmed their presence in respiratoryClinical Microbiology and Infection © 2015 European Society of Csamples wordwide [6–9]. A third PyV, Merkel cell poly-
omavirus (MCPyV), discovered soon after in a rare but
aggressive skin cancer [10], has been also detected at variable
frequencies in respiratory specimens [11–14].
The pathogenic role of recently discovered PyVs is much
debated. They were detected at similar rates in specimens from
symptomatic patients and persons without respiratory symp-
toms [6,8,14–16], but they appear to be signiﬁcant human
pathogens in immunosuppressed people [17,18]. To date, no
studies have evaluated the incidence of MCPyV, WUPyV and
KIPyV in patients with a high risk of pulmonary morbidity such
as CF patients. Although people with CF do not appear to have
higher rates of viral infection than those without CF, it is now
clear that the effects and clinical outcomes of these infections
are more severe [1,3,19]. To improve our knowledge on the
possible pathogenic role of MCPyV, WUPyV and KIPyV in CF,
we determined their prevalence in CF patients with or without
underlying conditions, i.e. Pseudomonas aeruginosa infection.Clin Microbiol Infect 2015; 21: 603.e9–603.e15
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
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603.e10 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMIPatients and methodsPatients and specimens
The study population consisted of 93 participants with CF
attending the Cystic Fibrosis Centre at the Brescia Children’s
Hospital between 1 July 2010 and 30 June 2011. Most patients
were sampled every 3 months, at regular visits or when
admission was required. The study was approved by the local
Etich Committee. Informed consent was obtained from patients
or their parents when necessary and human experimentation
guidelines for the conduct of clinical research were followed.
Respiratory samples, either sputum or nasopharyngeal aspi-
rates, were routinely collected for diagnostic purposes at each
of the 337 visits during the study period. To evaluate the
presence of P. aeruginosa and other bacterial pathogens, sam-
ples were seeded on sheep blood and chocolate agar plates.
Aliquots for virus detection were stored at −80°C until mo-
lecular analysis was performed.
One hundred nasopharyngeal aspirate specimens collected
from 100 patients who were admitted to the Civic Hospital in
Brescia for acute respiratory diseases were included in the
study as an age-matched control group (mean age 7.9 ± 5.7
years; median age: 7.25 years; range 0.2−22.5 years).
Nucleic acid extraction, RT-PCR and sequencing
Nucleic acid extraction was performed using the NucliSens
easyMAG system (bioMérieux, Marcy l’Étoile, France).
The presence of KIPyV, WUPyV and MCPyV has been
screened by nested PCR using a set of primers targeting a
fragment of the small T antigen of each virus. For virus-positive
samples, a second gene target was then ampliﬁed using primers
targeting the VP2 gene of each virus (see Supporting
information, Table S1). All the ampliﬁed fragments were puri-
ﬁed using WIZARD SV Gel and PCR CLEAN-UP SYSTEM (Promega,
Milan, Italy) and sequenced at the CRIBI BMR Genomics
Sequence Facility (Padua, Italy). All the MCPyV sequences in theFIG. 1. (a) Age distribution by samples (red bars) and patients (blue bars) p
individuals with cystic ﬁbrosis (CF). (b) Age distribution of CF patients by th
number of negative patients, whereas intermittently and chronically infected
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectdataset were aligned using CLUSTAL X software, then edited
manually to the BIOEDIT software (version 7.0.9).
Statistical analysis
Frequency of virus detection in respiratory specimens was
summarized by counts and proportions. Continuous variables
were expressed as mean ± SD if they were normally distrib-
uted, and if not they were expressed by median and range. The
chi-square test was used to evaluate the differences in the
occurrence of viral detection in the study groups and Mann–
Whitney U-test for non-normally distributed continuous vari-
ables was applied to analyse differences between patients. A
two-tailed value <0.05 was considered statistically signiﬁcant.ResultsPatient characteristics
A retrospective study aimed at evaluating the circulation rate of
the MCPyV WUPyV and KIPyV was conducted over the course
of 1 year. We tested a total of 337 respiratory samples from 93
subjects collected from July 2010 to June 2011. The median
number of specimens derived from the same patient was four
(range one to nine). There were no differences in the gender of
participants (sex ratio male to female: 1.2; n = 50 versus
n = 43). At the time of ﬁrst investigation the mean age of CF
patients was 9.6 ± 6.4 years whereas the median age was 8.1
years (range 0.2–23.8). One hundred and twenty-three speci-
mens (36.5%) were from children aged <5 years (28/93, 30.0%),
144/337 were from patients aged between 5 and 15 years (47/
93, 50.5%), the remaining 70 specimens were from young adults
>15 years old (18/93, 19.3%) (Fig. 1a).
Patients were divided into three sub-cohorts with respect to
their P. aeruginosa colonization status, according to the Leeds
criteria [20]. Of the CF patients analysed, 58/93 (63.4%) were
P. aeruginosa-negative (PaNeg), 21/93 (22.6%) were intermit-
tently infected (PaInt) and 14/93 (14.0%) were chronicallyositive for the presence of polyomaviruses in the respiratory tract of
eir Pseudomonas aeruginosa colonization status. Blue bars represent the
patients are represented by red and green bars, respectively.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 603.e9–603.e15
CMI Iaria et al. Polyomaviruses in cystic ﬁbrosis 603.e11infected (PaChr). The median age of the patients was 6.9 years
(range 0.1–24 years), 8.5 years (range 1–21 years) and 18 years
(range 6–23 years) for the negative, intermittent and chronic
groups, respectively. Patients aged <5 years were mostly PaNeg
(24/28, 85.7%), only 4/28 (14.3%) were PaInt and, among them,
one patient became PaChr during the course of the study. The
number of PaChr patients increased with age, being 5/47
(10.6%) within the 5–15 years patient group and 9/18 (50.0%)
within the >15 years group (Fig. 1b).
Viral detection study
Samples were considered PyV-positive only if the presence of
KIPyV, WUPyV and MCPyV genome was conﬁrmed by three
different assays (small TAg ampliﬁcation, VP2 ampliﬁcation,
amplicon sequencing). Among the 337 samples tested, the PyV
genome was detected in 94 samples (27.9%). Twenty-three
(6.8%) samples were MCPyV-positive, 30 (8.9%) were
WUPyV-positive and 41 (12.1%) were KIPyV-positive. Poly-
omaviruses were never detected in samples derived from 40
patients (43%) whereas 53 subjects (57%) were infected at least
once by one or more PyVs. During the observation period 4/53
virus-positive patients were co-infected by MCPyV and
WUPyV, 5/53 by MCPyV and KIPyV and 11/53 by WUPyV and
KIPyV. Among the patients evaluated, only one 13-year-old
patient experienced infection with all three PyVs. Concurrent
detection of two viruses was observed in nine patients (four
MCPyV- and WUPyV-positive patients; one MCPyV- and
KIPyV-positive patient; four WUPyV- and KIPyV-positive pa-
tients). It is worth noting that concurrent infection was the only
situation where WUPyV and MCPyV were detected in the same
patient.
The MCPyV-positive samples derived from 18 different pa-
tients and recurring MCPyV infection was observed in three of
them (16.7%). Interestingly, two patients showed positive
detection in two or more consecutive specimens and remained
positive for a period of 146 and 158 days (Fig. 2a). Similarly, 4/FIG. 2. Detection of (a) Merkel cell polyomavirus (MCPyV), (b) WU polyom
cystic ﬁbrosis (CF) with at least two positive specimens. Each line represent
no.). Diamonds indicate the day of specimen collection, where 0 is the day of
negative sample.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inf24 (16.7%) WUPyV-positive patients had two or more positive
samples and three of them showed infection in consecutive
samples (Fig. 2b). Consistent with a higher rate of incidence,
KIPyV was isolated at least twice in 6/32 (18.7%) patients and
four of them had consecutive KIPyV-positive specimens
(Fig. 2c).
Polyomaviruses were detected in every month during the
year of the study. The highest numbers of positive cases were
from November to January (38.2% of the months’ samples
were PyV-positive), with the peak incidence in December
(43.7% of the month’s samples). None of the analysed PyV
showed a striking seasonality; however, an analysis of MCPyV-
positive cases demonstrates a higher detection frequency of
MCPyV in autumn (60.9% of the total positive case detected
between October and December, p < 0.01) whereas WUPyV
and KIPyV showed a wider distribution pattern (Fig. 3). Finally,
we have retrospectively examined 100 respiratory samples
derived from a cohort of age-matched patients who were
admitted at the Brescia Hospital with a diagnosis of acute res-
piratory disease. Despite the fact that, in contrast to the CF
patient cohort, the control population was composed of sub-
jects with an ongoing acute respiratory disease, results obtained
conﬁrmed that PyVs were more frequently detected in CF
patients than in patients suffering from acute respiratory dis-
eases (Table 1).
Risk factors for PyV detection
No gender preponderance in the incidence of PyV infection was
observed (28/50 males versus 25/43 females, p 0.83) and similar
results were obtained when patients positive for MCPyV (8/50
males versus 10/43 females, p 0.37) WUPyV (11/50 males
versus 13/43 females, p 0.36) and KIPyV (17/50 males versus
15/43 females, p 0.9) were evaluated separately. PyV-infected
patients (median age 8.5 years; range 0.2–23 years) did not
show a signiﬁcant age difference when compared with the PyV-
negative population (median age 9 years; range 0.1–24 years) (pavirus (WUPyV), and (c) KI polyomavirus (KIPyV) DNA in patients with
s one patient shown with his/her numerical identiﬁcation code (Patient
ﬁrst sampling. Black diamond: PyV-positive sample; white diamond: PyV-
ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 603.e9–603.e15
FIG. 3. Number of specimens evaluated for the presence of poly-
omaviruses (PyVs) by month of sampling. Blue bars represent the
number of negative samples, whereas positive samples are represented
with purple (KI PyV), green (WU PyV) and red (Merkel cell (MC) PyV)
bars.
603.e12 Clinical Microbiology and Infection, Volume 21 Number 6, June 2015 CMI0.88). Moreover, no difference was observed in the relative
prevalence of PyV infection in patients younger than 5 years
(57.1%, 16/28) compared with older children (5–15 years,
57.4% (27/47)) or to young adults (>15 years, 55.5% (10/
18)).This result was conﬁrmed when patients positive for
MCPyV (<5 years, 10.3% (3/29); 5–15 years, 20.7% (12/58);
>15 years, 13.6% (3/22) with p 0.22 and p 0.72, respectively)
WUPyV (<5 years, 20.7% (6/29); 5–15 years, 20.7% (12/58);
>15 years, 18.2% (4/22) with p 1.00 and p 0.82, respectively)
and KIPyV (<5 years, 27.6% (8/29); 5–15 years, 27.6% % (16/
58); >15 years, 27.3% (6/22) with p 1.00 and p 0.98, respec-
tively) were analysed separately.TABLE 1. Frequency of poyomavirus detection in cystic











KIPyV 32 (34.4%)* 8 (8%)* 41 (12.1%) 8 (8%)
WUPyV 24 (25.8%)* 4 (4%)* 30 (8.9%) 4 (4%)
MCPyV 18 (19.3%)* 3 (3%)* 23 (6.8%) 3 (3%)
Concurrent
detection of
at least 2 PyVs
9 (9.7%)* 0 (0%)* 9 (9.7%) 0 (0%)
Total occurrence 53 (57%)* 15 (15%)* 94 (27.9%) 15 (15%)
Abbreviations: ARD, acute respiratory disease; CF, cystic ﬁbrosis; KIPyV, KI
polyomavirus; MCPyV, Merkel cell polyomavirus; WUPyV, WU polyomavirus.
*Signiﬁcant differences between CF and ARD populations (chi-square test).
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectHowever, when the samples derived from these patients
were evaluated, a strikingly signiﬁcant difference was observed
in the prevalence of PyV infections in samples derived from
patients <5 years (17.9%, 22/123) compared with those derived
from older children (5–15 years) (37.5%, 54/144) (p < 0.01).
The difference among samples from children <5 years and
young adults >15 years (25.7%, 18/70) followed the same trend
but was less evident and not signiﬁcant (p 0.09). This was mainly
due to the small number of MCPyV-positive (3.2%, 4/123) and
KIPyV-positive (7.3%, 9/123) samples detected from children
<5 years old in comparison with MCPyV-positive (9.0%, 13/
144) and KIPyV-positive (16.7%, 24/144) samples detected from
5–15-year old patients (p 0.05 and p 0.02, respectively).
Patients with CF belonging to the cohort examined were
frequently colonized by different bacterial pathogens. The most
common pathogen detected in the respiratory samples was
Staphylococcus aureus, which was detected in 43/94 PyV-positive
samples (45.7%) and 103/243 (42.4%) PyV-negative samples. In
PyV-positive patients, evaluation of sequential samples collected
within the 6 months before virus detection corroborated this
observation. In fact, incidence of S. aureus isolation in the
months preceding PyV detection (65/170, 38.2%) did not differ
from that observed at the time of PyV detection (see
Supporting information Table S2). Moreover, when three
sequential samples from PyV-negative patients were evaluated
in a 6-month-long follow up, frequency of S. aureus isolation
was also superimposable (47/120, 39.2%) with the one
described in PyV-positive patients (data not shown).
Analysis of incidence of PyV infection with respect to
P. aeruginosa colonization status has shown no difference among
the patients belonging to the three cohorts of PaChr (64.3%, 9/
14), PaInt (52.4%, 11/21) and PaNeg (56.9%, 33/58). However,
evaluation of the incidence of MCPyV, WUPyV and KIPyV has
highlighted that detection of MCPyV-positive samples was more
frequent in PaChr (35.7%, 5/14) than in PaInt (19.0%, 4/21) or
PaNeg subjects (15.5% 9/58), even if, due to the low number of
chronic patients, results are not signiﬁcant (p 0.27 and p 0.09,
respectively). The same trend was observed for WUPyV
(PaChr 42.8%, 6/14; PaInt 23.8%, 5/21; PaNeg 22.4%, 13/58) (p
0.23 and p 0.12, respectively), whereas KIPyV incidence was
similar in the three sub-cohorts (PaChr 42.8%, 6/14; PaInt
38.1%, 8/21; PaNeg 31.0%, 18/58).
When the total number of positive samples was analysed, we
observed that 27.8% (15/54) of samples from PaChr, 29.9% (26/
87) from PaInt and 22.4% (44/196) from PaNeg were PyV-
positive. It is worth noting that ﬁve of the 15 PyV-positive
samples from PaChr showed a co-infection (33.3%) with two
viruses (MCPyV and WUPyV n = 2; WUPyV and KIPyV n = 2;
MCPyV and KIPyV n = 1) whereas only 1/26 (3.8%) PaInt
samples (WUPyV and KIPyV) and 3/44 (6.8%) PaNeg samplesious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 603.e9–603.e15
CMI Iaria et al. Polyomaviruses in cystic ﬁbrosis 603.e13(MCPyV and WUPyV n = 2; WUPyV and KIPyV n = 1) showed
the concurrent presence of PyVs (p < 0.05 and p < 0.01,
respectively). Furthermore, a signiﬁcantly higher incidence of
MCPyV in samples derived from PaChr patients compared with
PaInt and PaNeg samples, was observed (p < 0.05) (Table 2).
In an attempt to better characterize if the presence of
P. aeruginosa in the lung of CF patients may facilitate PyV in-
fections, we evaluated whether sequential samples collected
within 6 months before virus detection from PyV-positive pa-
tients showed a higher incidence of P. aeruginosa isolation in the
months preceding PyV detection, compared with those patients
who were PyV-negative. Twenty out of 53 patients positive for
PyVs at D 0 suffered from at least one P. aeruginosa infection
during the observation period (from D –180 to D –30) (37.7%)
and, among them, 7/18 were MCPyV-positive patients (38.8%),
10/26 were WUPyV-positive patients (38.5%), and 10/32 were
KIPyV-positive patients (31.2%) (Table S2). On the other hand,
within the 34 patients negative for PyVs at D 0 from whom
longitudinal analysis was available, only 7 (20.6%) showed the
presence of P. aeruginosa in one or more samples examined
between D –180 and D –30 (data not shown). Taken together
these results strengthen the hypothesis that P. aeruginosa may
play a role in increasing the susceptibility to PyV infection/
reactivation.
Association between PyV detection and P. aeruginosa
infection
During the period of observation 66 P. aeruginosa were isolated.
As expected, isolation of P. aeruginosa was signiﬁcantly more
frequent in samples derived from PaChr patients (72.2%, 39/54)
than from PaInt (19.5%, 17/87) and PaNeg (5.1%, 10/196) pa-
tients (p < 0.01). Samples with a P. aeruginosa-positive culture
had a slightly greater incidence of PyV detection (30.3%, 20/66)
than P. aeruginosa-negative samples (23.9%, 65/271). Again, in
P. aeruginosa-positive samples we observed a higher incidence
of co-infection (30.0%, 6/20) in comparison with the co-
infection incidence observed in P. aeruginosa-negative samples
(4.6%, 3/65) (p < 0.01). When the incidence of KIPyV, WUPyV
and MCPyV was analysed, we observed that MCPyV was more
frequently present in P. aeruginosa-positive samples (13.6%, 9/TABLE 2. Polyomaviruses detected in patients with cystic ﬁbrosis ca
KIPyV W
Positive patients Positive samples P
PaChr (Patients n = 14; Samples n = 54) 6 6
PaInt (Patients n = 21; Samples n = 87) 8 15
PaNeg (Patients n = 58; Samples n = 196) 18 20 1
Abbreviations: KIPyV, KI polyomavirus; MCPyV, Merkel cell polyomavirus; PaChr, chronicall
PaNeg, P. aeruginosa-negative; WUPyV, WU polyomavirus.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Inf66) than in P. aeruginosa-negative (5.2%, 14/271) samples
(p < 0.05) whereas no signiﬁcant differences were detected for
WUPyV (10.6% (7/66) in P. aeruginosa-positive versus 8.5% (23/
271) in P. aeruginosa-negative p 0.58) and KIPyV (15.1%(10/66)
in P. aeruginosa-positive versus 11.4% (31/271) in P. aeruginosa-
negative p 0.45).DiscussionSeverity and clinical importance of bacterial infection in CF
patients have deferred the extensive need for viral testing.
Evaluation of respiratory viruses in CF specimens has only been
recently reported and, to our knowledge, this is the ﬁrst report
that provides a detailed evaluation of KIPyV, WUPyV and
MCPyV detection in respiratory tract samples obtained from
children and young adults with CF. In the last few years, several
studies have shown a higher rate of WUPyV and KIPyV
detection in respiratory specimens from haematology/oncology
[9,18,21,22]. and AIDS [23] patients, suggesting that immuno-
suppression may result in reactivation of these viruses. Our
longitudinal retrospective study assessed a prevalence of PyVs
in the respiratory secretions of CF patients that was higher than
that indicated in previous reports in immune competent per-
sons, both asymptomatic and with respiratory symptoms
[4,11,24]. This result suggests that patients with underlying
respiratory tract diseases like CF, despite the absence of
immunosuppression, could develop a greater susceptibility to
PyV infection. Interestingly, even if acute respiratory illnesses
are frequently associated with increased lower respiratory tract
morbidity in CF patients, no differences in the occurrences and
seasonal distributions of ‘canonical’ respiratory viruses has been
described [25,26]. Therefore, the high rate of PyV detection we
observed might be explained by the presence of a microenvi-
ronment in the lung of CF patients that is favourable to PyV
infection [27] or, alternatively, by a tendency to reactivate
latent virus [22]. Analysis of MCPyV sequences derived from
the CF patients cohort does not allow the production of a
phylogenetic tree and is therefore not useful to discriminate
between reactivation or reinfection. However, in this respect, ittegorized for their Pseudomonas aeruginosa colonization status
UPyV MCPyV
ositive patients Positive samples Positive patients Positive samples
6 6 5 8
5 8 4 4
3 16 9 11
y infected with Pseudomonas aeruginosa; PaInt, intermittently infected with P. aeruginosa;
ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 603.e9–603.e15
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for sequence analysis, genome diversity of known MCPyV iso-
lates is very low, with nucleotide identity across different iso-
lates being greater than 98.5% (see Supporting information,
Fig. S1).
In CF patients a correlation between the presence of bacterial
pathogens and respiratory viruses has been long suggested
[26,28] and recently Scheithauer et al. [29] highlighted an asso-
ciation of respiratory virus positivity with colonization by
P. aeruginosa. Our results demonstrated that the presence of
KIPyV or WUPyV does not correlate with the status of
P. aeruginosa colonization as well as with the concurrent pres-
ence of P. aeruginosa infection at the time of sampling, enforcing
the hypothesis that detection of these viruses may not be the
cause or the effect of detrimental respiratory conditions. On the
contrary, MCPyV was signiﬁcantly associated with the presence
of P. aeruginosa infection and its detection was more frequent in
patients that were deﬁned as chronic for P. aeruginosa coloni-
zation. Furthermore, we observed that sequential samples
collected within the 6 months before virus detection from PyV-
positive patients showed a higher incidence of P. aeruginosa
isolation in the months preceding MCPyV detection, compared
with those patients who were PyV-negative. Data from this
study, combined with those obtained by other groups [22,23],
indicate that MCPyV infection/persistence reactivation may
follow different rules to those for KIPyV and WUPyV. Goh et al.
[14] demonstrated that MCPyV is more frequently found in
respiratory samples derived from adults, particularly among the
elderly. In this respect, it can be hypothesized that association of
MCPyV infection with the status of being a PaChr patient can be
because the PaChr population mostly comprises older CF pa-
tients. However, the signiﬁcantly higher presence of MCPyV in
CF patients suffering from P. aeruginosa colonization was
detected either in PaChr (four MCPyV-positive samples out of
39 P. aeruginosa-positive samples) PaInt (three MCPyV-positive
samples out of 17 P. aeruginosa-positive samples) and PaNeg
(two MCPyV-positive samples out of ten P. aeruginosa-positive
samples) suggesting that association between the presence of
MCPyV and P. aeruginosa isolation may be age-independent. A
possible explanation for the higher occurrence of MCPyV in
PaChr and P. aeruginosa-colonized patients is that the respiratory
tract of individuals with CF could be a privileged site of MCPyV
persistence where viral reactivation can occur as a consequence
of P. aeruginosa stimulation. Even if the lack of knowledge of
which cells are the primary target of MCPyV infection and viral
reservoirs still impedes proving this hypothesis, it is conceivable
that virus reactivation induced by P. aeruginosa may, in turn,
contribute to pulmonary inﬂammatory processes and that the
consequent damage induced by viral replication and the virus-
induced immunosuppression may facilitate bacterialClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectcolonization and superinfections. In conclusion, P. aeruginosa and
McPyV infections might have synergistic actions in favouring
each other’s persistence in the lung microenvironment of pa-
tients with CF. Clearly, further studies are needed to elucidate
what role, if any, PyVs plays in the respiratory illness of CF
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